Recent 8-K filings for NVCT
Highest-materiality recent filing
Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in ARID1a-deficient ovarian cancers
- FDA granted Orphan Drug Designation for NXP800 for treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
- CEO Ron Bentsur noted prevalence exceeds 200,000 threshold; designation for a disease subset is uncommon.
-
Nuvectis Pharma Q1 2026 net loss $6.1M; cash $25.1M; NXP900 Phase 1b data expected summer
Cash and equivalents $25.1M as of March 31, 2026, down from $31.6M at Dec 31, 2025.
-
Nuvectis Pharma reports FY2025 net loss $26.4M; cash $31.6M; NXP900 program advancing
Net loss $26.4M for FY2025 vs $19.0M in FY2024; includes $6.0M stock-based comp and $2.4M milestone license fees.
-
Nuvectis Pharma Q3 net loss $7.5M; cash $35.4M; NXP900 Phase 1b underway
Cash $35.4M at Sep 30, 2025, up from $18.5M at Dec 31, 2024; runway into 3Q2027.
-
Nuvectis Pharma appoints biotech executive Juan Sanchez, MD to Board of Directors
Juan Sanchez, MD appointed to board effective Sept 22, 2025; term expires at 2026 annual meeting.
-
Nuvectis reports Q2 net loss of $6.3M; NXP900 Phase 1a complete; cash ~$39M proforma
Net loss of $6.3M for Q2 2025 vs $4.4M for Q2 2024; increase driven by NXP900 DDI study and stock-based compensation.
-
Nuvectis Pharma shareholders elect director, ratify auditor at 2025 annual meeting
Quorum of 14,605,167 shares (61.86%) present out of 23,606,443 outstanding shares.
-
Nuvectis Pharma establishes $60M ATM with Leerink Partners; terminates prior HC Wainwright program
New ATM agreement with Leerink Partners to sell up to $60M of common stock; 3.0% commission on gross proceeds.
-
Nuvectis Pharma Q1 2025 net loss $5.3M; cash $29.9M; NXP900 Phase 1b advancing
Cash and equivalents $29.9M as of Mar 31, 2025, up from $18.5M at Dec 31, 2024, driven by $14.0M net public offering proceeds.
-
Nuvectis Pharma reports FY2024 net loss of $19.0M; follow-on offering extends cash runway into 2027
Cash and cash equivalents $18.5M as of Dec 31, 2024, down from $19.1M; net loss $19.0M, vs $22.3M in 2023.
-
Nuvectis Pharma prices $13.5M public offering at $5/share; full over-allotment exercised
Priced 2.7M shares at $5.00 for $13.5M gross; underwriter fully exercised over-allotment of 405k shares, total gross $15.5M, net ~$14.4M.
-
Nuvectis Pharma Q3 2024 net loss $4.2M; NXP800 data update expected November
Net loss $4.2M in Q3 2024 vs $5.9M Q3 2023; R&D expenses $2.8M vs $4.5M.
-
Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in ARID1a-deficient ovarian cancers
FDA granted Orphan Drug Designation for NXP800 for treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
-
Nuvectis Q2 2024 net loss narrows to $4.4M; progressing NXP800 and NXP900 trials
Cash $18.1M at June 30, 2024, down $1.4M from March 31, 2024; net loss $4.4M vs $5.8M YoY.
-
Nuvectis Pharma stockholders re-elect directors and ratify auditor at 2024 annual meeting
Kenneth Hoberman elected Class II director with 8,026,155 votes for, 809,797 against.
-
Nuvectis Q1 2024 net loss $4.2M; cash $19.5M; NXP800 Phase 1b data encouraging
Net loss $4.2M in Q1 2024 vs $4.0M in Q1 2023; cash $19.5M (up from $19.1M in Dec 2023).
-
Nuvectis Pharma FY2023 net loss $22.3M; cash $19.1M; NXP800 data update expected March 2024
Cash and cash equivalents $19.1M at Dec 31, 2023, down from $20.0M at Dec 31, 2022.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.60 · Most common event earnings